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Abstract
This article provides guidelines for organ and tissue sampling adapted to porcine animal models in translational medical research.
Detailed protocols for the determination of sampling locations and numbers as well as recommendations on the orientation, size,
and trimming direction of samples from *50 different porcine organs and tissues are provided in the Supplementary Material. The
proposed sampling protocols include the generation of samples suitable for subsequent qualitative and quantitative analyses,
including cryohistology, paraffin, and plastic histology; immunohistochemistry; in situ hybridization; electron microscopy; and
quantitative stereology as well as molecular analyses of DNA, RNA, proteins, metabolites, and electrolytes. With regard to the
planned extent of sampling efforts, time, and personnel expenses, and dependent upon the scheduled analyses, different protocols
are provided. These protocols are adjusted for (I) routine screenings, as used in general toxicity studies or in analyses of gene
expression patterns or histopathological organ alterations, (II) advanced analyses of single organs/tissues, and (III) large-scale
sampling procedures to be applied in biobank projects. Providing a robust reference for studies of porcine models, the
described protocols will ensure the efficiency of sampling, the systematic recovery of high-quality samples representing the entire
organ or tissue as well as the intra-/interstudy comparability and reproducibility of results.
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Introduction
Pigs are increasingly being used as disease models in transla-
tional medicine and as large animal model systems in surgery,
transplantation research, and toxicologic pathology (Aigner
et al. 2010; Gun and Kues 2014; Lunney 2007; Wuensch et al.
2014). The growing popularity of porcine models in biomedical
research is due to several advantageous similarities between
pigs and human beings that cannot be reproduced adequately
in classical rodent models (Aigner et al. 2010). Due to the prox-
imity to human anatomy, physiology and body dimensions, the
comparably short generation interval (1 year), and high fertility
rates, pigs are an ideal model organism for basic research and the
study of disease mechanisms as well as model organisms for
testing novel surgical and pharmacological therapeutic strate-
gies (Aigner et al. 2010). Moreover, sound molecular biological
methods for genetic modification of pigs are currently available,
allowing for generation of tailored porcine large animal models
for diverse human diseases (Aigner et al. 2010; Klymiuk et al.
2010; Klymiuk et al. 2012a; Kurome et al. 2015; Wu et al. 2013).
Such genetically modified pig models have successfully been
established for cystic fibrosis, diabetes mellitus, Duchenne mus-
cular dystrophy, and other important human diseases (Aigner
et al. 2010; Gun and Kues 2014; Klymiuk et al. 2013; Klymiuk
et al. 2012b; Lunney 2007; Renner et al. 2013; Wolf et al. 2014).
The potential of tailored pig models for testing targeted thera-
pies is outlined by Klymiuk et al. in this issue of Toxicologic
Pathology (Klymiuk et al. 2015).
Deriving optimal benefit from porcine animal models
requires experimental study designs and examination protocols
that warrant representative samples, reproducible results, and
comparable analyses between different studies and
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investigators. Here, the applied mode of selection of biological
samples, including the location, size, number, and orientation,
is of great importance because it will affect the results of the
subsequent investigations, ranging from histological examina-
tions to molecular profiling analyses. In rodent models, the
introduction and broad application of guidelines for the stan-
dardized generation of samples have greatly contributed to the
quality as well as to the intra- and interstudy comparability of
results (Kittel et al. 2004; Morawietz et al. 2004; Ruehl-Fehlert
et al. 2003). Comparable sampling guidelines have not been
established so far for porcine models.
However, rodent sampling protocols cannot be directly
adapted to pig models because there are considerable differ-
ences in the anatomy and size of porcine and rodent organs/
tissues. In addition to physical and anatomic features, several
other important aspects have to be considered in the sampling
strategies for porcine animal models. The considerably longer
generation interval of pigs compared to rodents, as well as the
significantly higher costs, time, and personnel efforts required
for the generation of porcine models and for pig husbandry,
limits the number of available animals.
Therefore, the individual animals of a respective porcine
model and the samples generated from these pigs are particu-
larly valuable, especially if genetically modified pigs and/or
long-term experimental issues, such as prolonged disease
courses, are to be examined. In the course of any study, addi-
tional experiments, which had not been scheduled at the begin-
ning, might later turn out to be relevant. If suitable samples for
such additional experiments are not available, they have to be
generated from additional animals. Particularly, if aged pigs of
genetically modified models are examined, the efforts that have
to be deployed for the generation of additional animals are
considerably higher than in corresponding rodent models.
In light of the steadily growing relevance of pig models in
biomedical research and species-specific differences, the
implementation of uniform and standardized protocols for sam-
ple generation from porcine organs and tissues applicable to a
wide range of subsequent types of analyses is urgently needed
to take full advantage of the translational value of porcine
animal models. The proposed guidelines will allow the gener-
ation of comparable and reproducible high-quality specimens
and might reduce the number of animals needed in a study by
avoiding the unnecessary sacrifice of valuable animals for the
repeated generation of samples (Tornqvist et al. 2014).
Sampling Guides for Porcine Organs
and Tissues
In total, sampling protocols for *50 porcine organs and tissues
(see Supplementary Material), adjusted to the expenditures and
scopes of the following 3 different study types, are provided:
Type I: Routine screenings for the detection of histo-
pathological organ alterations in new porcine models,
studies examining general gene expression patterns in
organs/tissues, and general toxicity studies.
Type II: Advanced examinations of distinct organs/tis-
sues, with the generation of a sufficient number of
backup samples, suitable for a wide range of diverse
analyses, including analyses not specified at the time
point of sampling.
Type III: Biobank projects, requiring large-scale sam-
pling procedures to generate high numbers of various
different types of samples suitable for as many differ-
ent types of analyses as possible, taken from a broad
spectrum of different organs/tissues.
The respective protocols are designed to fit the demands of
the industrial standards of the pharmaceutical industry and
toxicologic pathology. They have been developed based on
extensive experiences in pig toxicopathology, in pathomorpho-
logical characterization of numerous genetically modified pig
models, and in porcine animal model biobanking (Abbott 2015;
Aigner et al. 2010; Kemter et al. 2012; Klymiuk et al. 2013;
Klymiuk et al. 2012a; Klymiuk et al. 2012b; Klymiuk et al.
2012c; Renner et al. 2010, 2012, 2013; Streckel et al. 2015;
Wuensch et al. 2014). The proposed sampling protocols are
intended as general guidelines but not as requirements for the
sampling of tissues in any porcine model. The protocols can
generally be applied to the organs/tissues of pigs weighing
*10 to *400 kg and can be modified accordingly if smaller
or younger animals are examined.
In studies of the first type (I) or in experiments that, in
addition to a different main experimental task, a broad set of
organs/tissues has to be examined in a routine, overview fash-
ion by standard analyses methods, the applied sampling proto-
cols allows for fast, uncomplicated and less elaborate sampling.
Therefore, type I study sampling protocols include the collec-
tion of a limited number of samples per organ/tissue taken from
deliberately defined locations, with uniform sample sizes and
predefined orientations/cutting directions of a histological spe-
cimen. Type I sampling is considered adequate for the identi-
fication of qualitative histopathological changes and general
organ-/tissue-specific gene expression patterns in routine stud-
ies. If organs/tissues display macroscopically evident patholo-
gical alterations, additional samples for histopathology,
microbiology, virology, and molecular analyses are taken from
the altered sites, as appropriate.
The list of porcine organs and tissues scheduled for routine
examination in type I studies and lists of organs/tissues recom-
mended for pathohistological examination in routine toxicity
studies in rodent and nonrodent species by the Society of Tox-
icologic Pathology (STP) and by different public institutions
and regulatory authorities are shown in Table 1. Except for
rodent-specific organs, all organs and tissues regularly evalu-
ated in other species are also examined in porcine models.
Additionally, the generation of samples for histopathology and
molecular analyses is scheduled for some porcine organs/tis-
sues, which are not regularly included in established sampling
guidelines for routine toxicity studies. These include organs
and anatomical structures that are sampled because they are
characteristically well developed in pigs, such as the









































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































bulbourethral gland and the palatine tonsil, or because they
represent routinely examined predilection sites for pathological
alterations in certain porcine diseases, such as the ileal papilla
in swine dysentery. Sampling of other tissues and organs
included in the type I study sampling list, such as adipose
tissue, tendons, middle and inner ear structures, the urethra,
the spermatic cord, the penis, and the prepuce, may be skipped
in routine toxicity studies if no gross lesions are present at
necropsy and no clinical findings support a histopathological
examination. However, when genetically modified, ‘‘new’’
porcine models are necropsied for an initial, overall pathologi-
cal examination, the rare opportunity to collect and examine
these ‘‘uncommon’’ tissues/structures should be used.
The sampling protocols designed for type II and III studies
are particularly designed for the examination of genetically
modified pig models and allow for the generation of samples
that are quantitatively and qualitatively suitable for a large(r)
range of possible subsequent analyses. Aside from the genera-
tion of samples for the analyses actually scheduled in the
experimental design of a specific study, sampling protocols for
type II and III studies also provide the opportunity to generate
sufficient numbers of differentially processed backup samples
for additional types of analyses in advance. Furthermore, these
protocols allow for the provision of a comprehensive biobank
collection of redundant, adequately processed samples from
any organ or tissue of potential interest (Abbott 2015). The
spectrum of possible downstream analyses may include
descriptive and quantitative histopathological analyses, such
as histological examinations of differentially fixed samples and
samples embedded in different embedding media, including
paraffin or plastic resin as well as frozen-section histology,
immunohistochemistry, in situ hybridization, electron micro-
scopy, and quantitative stereological analyses. Additionally,
clinical laboratory diagnostic analyses as well as DNA, RNA,
and protein analyses including holistic OMICS profiling of
frozen, and of otherwise preserved, sample materials might
be performed.
Wherever applicable, type II and III sampling protocols
schedule volume-weighted systematic random sampling proce-
dures (Gundersen and Jensen 1987) for several organs, includ-
ing the liver, spleen, kidneys, adrenal and thyroid glands,
pancreas, salivary glands, thymus, and lungs. In this instance,
the sampling positions and numbers of samples to be taken are
based on stochastic parameters and depend on anatomic–mor-
phological and functional properties of the respective organ/
tissue. These sampling regimes ensure sampling of representa-
tive specimens, avoid systematic sampling biases, reduce
experimental variability, and efficiently increase the precision
of the overall experiment (Howard and Reed 2005). From each
of the systematically randomly determined sampling positions,
multiple samples are harvested and differentially processed
according to the respective scheduled subsequent analyses.
This time- and labor-saving principle may easily be adjusted
to the individual sample-number and sample-type demands of a
specific study. An exception to the general systematic random
sampling approaches, where the entire organ is sampled, was
made in organs/tissues with numerous and/or complexly struc-
tured morphologic components, such as the central nervous
system or the heart, where the necessary number of sampling
sites determined by systematic random sampling over the total
organ would be exceedingly disproportionately high and there-
fore impractical. Therefore, in these organs, samples are taken
from defined locations, such as defined brain areas, or distinct
cardiac structures that are of interest in a specific experiment. If
appropriate, the excised tissue regions of interest are then sub-
jected to a subsequent random sampling procedure to generate
representative subsamples for different downstream analyses.
In practice, the workload, the personnel requirements, and the
time frame and temperature conditions of a distinct sampling
procedure must be compatible with the requirements of the
study design and the scheduled analyses. Thus, unless the pri-
mary scientific scope of a study necessarily requires systematic
random sampling of the entire organ/tissue, taking samples
from defined anatomical locations appears sufficient for most
qualitative histopathological and molecular–biological analy-
ses in tissues, such as the mammary glands, adipose tissue,
skin, and skeletal musculature.
For selected organs, study type II and III sampling protocols
additionally present appropriate methods for the determination
of the total organ (i.e., the reference compartment) volumes by
Cavalieri volumetry or via the determination of the specific
density of the tissue (Howard and Reed 2005; Scherle 1970).
Moreover, the generation of backup specimens suitable for
quantitative histomorphological analyses requiring isotropic
uniform random–sectionable and vertical uniform random–sec-
tionable samples is routinely scheduled in type II and type III
study sampling protocols for several organs/tissues. These
samples enable the assessment of a wide range of quantitative
stereological parameters that might yet emerge to be of interest
in later courses of a study and could not be adequately deter-
mined without the respective specimen (Gundersen et al. 2013;
Howard and Reed 2005). Further information on the practical
application of systematic random sampling, volumetry, and
sample processing for quantitative stereological analyses is




The sampling protocols proposed in the Supplemental Material
provide detailed descriptions of applicable sampling proce-
dures (type I–III studies) for different organs/tissues and vari-
ous different downstream analyses, as illustrated by schematic
drawings, macroscopic images, and histological images. The
initial section presents different sampling strategies applicable
to porcine organs and tissues, the determination of the specific
density of porcine tissues, organ volumetry, estimation of
embedding-related tissue shrinkage, and the generation of sam-
ples for quantitative stereological analyses. The sampling
guides for the different organs/tissues usually cover particular
information on the following topics:
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(1) Relevant pig-specific anatomic features and practical
recommendations regarding the preparation of dif-
ferent organs/tissues.
(2) Cutting directions and orientations of samples for
histopathological examinations. The symbols used
to indicate different cutting directions, sample orien-
tations, and section planes in schematic drawings and
photo images are explained in Supplemental
Figure S14.
(3) Sample numbers/locations. For routine screenings in
type I studies, the anatomic location of the samples to
be taken from the respective organs/tissues is indi-
cated. The number of samples that has to be taken by
systematic random sampling generally depends on
the size of the organ/tissue, the size of the tissue
sample pieces, the statistical properties of the inves-
tigated parameters, such as interindividual/biological
and interspecimen variances, as well as the type and
extent of the scheduled subsequent analyses. There-
fore, the sample numbers indicated in the sampling
guidelines merely represent recommended guidance
levels, which should generally be sufficient for most
analyzed parameters. Depending on the investigated
parameter, the actual number of necessary sampling
positions per organ/tissue might, thus, be lower for a
specific experiment.
(4) Individual sample sizes and specific tissue processing
methods for different downstream analyses. The max-
imal size of an individual sample is limited by differ-
ent factors, including the size of the respective organ,
the number of samples to be harvested, and the spe-
cific conditions of the subsequent processing of the
sample, such as the maximal penetration depth of
fixatives and the size of embedding cassettes and test
tubes. The dimension of individual samples desig-
nated for molecular analyses is approximately 3 
3  3 mm. These samples are frozen on dry ice and
then stored at 80C until further analysis. The size
of samples to be processed for histological examina-
tion is usually up to 2  2  0.5 cm for paraffin-
embedded specimens, *1  1  0.5 cm for plastic
resin (glycol methacrylate/methylmethacrylate
[GMA/MMA])-embedded specimens, 1  1 
0.5 cm for cryohistology samples, and 2  2  2
mm for the glutaraldehyde-fixed specimen. The stan-
dard fixatives used in the present guidelines are 10%
formalin (4% neutrally buffered formaldehyde solu-
tion), fixation for 24 hr at room temperature (RT);
methacarn solution (60% absolute methanol, 30%
chloroform, 10% glacial acetic acid v/v), fixation for
24 hr at RT, samples are then rinsed in 70% ethanol
and tissue processing for paraffin embedding is
started in 70% ethanol; and glutaraldehyde solution
(2.5% or 6.25% in Sorensen’s buffer, as indicated).
For cryosectioning, tissue specimens are embedded
in Tissue-Tek1 O.C.T.™-blocking medium (Sakura
Finetek Europe B.V., the Netherlands), frozen in
liquid nitrogen-cooled isopentane and stored at
80C until sectioning. Alternatively, the samples
can be frozen in dry ice-cooled isopentane without
a blocking medium to include methods such as the
mass spectrometry imaging in the spectrum of possi-
ble downstream analyses (Goodwin et al. 2011).
Formalin-fixed bone specimen are decalcified, using
a slow-acting, acid-based decalcification solution
(DC3; Labonord, Germany) for 3–30 days at RT. The
embedding media for samples used for histological
and quantitative histopathological analyses are
paraffin, glycidyl ether (Epon) resin, and GMA/
MMA (Hermanns, Liebig, and Schulz 1981). Non-
standard materials used for sampling/tissue process-
ing are specified in the descriptions of the respective
sampling protocols. For a simplified presentation, the
different downstream analysis types are indicated by
pictograms (Supplemental Figure S15).
(5) A comparison of the study type I sampling protocols
with established recommendations for histopatholo-
gical examinations in routine toxicity studies in
rodents. For each organ/tissue, the similarities and
differences between the type I study sampling proto-
cols for porcine models, standard guidelines for organ
sampling and trimming in rats and mice (Kittel et al.
2004; Morawietz et al. 2004; Ruehl-Fehlert et al.
2003), and applicable ‘‘Best Practices’’ guides of
Working Groups of the STP are discussed (Bolon
et al. 2013; Haley et al. 2005; Reagan et al. 2011).
(6) The recommended cross grid sizes for systematic ran-
dom sampling procedures.
(7) Schematic illustrations are provided where appropri-
ate and are drawn in gray scales to preserve the recog-
nizability of image details in black and white
printouts.
(8) Histological images. In the type I study sampling
guidelines, HE-stained histological images of the
indicated section planes are provided, with the rele-
vant tissue structures indicated.
(9) Estimates of the expected time and personnel efforts
for sample collection in type II and III studies.
(10) References to the most relevant literature.
Conclusions
Because of the increasing importance of porcine animal models
in biomedical research, the application of consistent and appro-
priate sampling procedures for tissue evaluation will increase
the quality of these studies. The sampling protocols provide a
basis for the generation of representative, high-quality samples
using standardized procedures, which will contribute to the
validity of inter- and intrastudy comparisons in porcine studies.
The proposed sampling procedures and indicated sample num-
bers and sizes are intended as guidelines for sampling organs/
418 Toxicologic Pathology 44(3)
tissues in pigs but not as requirements that must be met in any
research project involving porcine animal models. The differ-
ent sampling protocols for the type I, II, and III studies can be
combined and individually adjusted to the protocol-defined
objectives of a specific research project. The proposed ‘‘for-
ward-looking’’ sampling strategies ensure that all necessary
samples are correctly collected and processed for a given study
so that they might contribute to a reduction in the number of
animals needed in a study (Tornqvist et al. 2014).
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